

# Salim I Khakoo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4338713/publications.pdf>

Version: 2024-02-01

105  
papers

7,509  
citations

109137

35  
h-index

53109

85  
g-index

134  
all docs

134  
docs citations

134  
times ranked

8201  
citing authors

#	ARTICLE	IF	CITATIONS
1	Testing key underlying assumptions of respondent-driven sampling within a real-world network of people who inject drugs. <i>International Journal of Social Research Methodology: Theory and Practice</i> , 2022, 25, 91-102.	2.3	1
2	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 <sup>2</sup> . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.	2.6	6
3	Immunotherapy for hepatocellular carcinoma: a "CRAFTY" approach to patient stratification. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 327-329.	0.7	1
4	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. <i>Journal of Immunology</i> , 2022, 209, 379-390.	0.4	5
5	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.	1.9	5
6	A spotlight on natural killer cells in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021, 74, 254-255.	1.8	1
7	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. , 2021, 5, 304-322.		2
8	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
9	Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors. , 2021, 9, e001912.		10
10	Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1274-1283.	1.0	2
11	PWE-16...Injecting network structure determines the most efficient strategy for Hepatitis C elimination. , 2021, , .		0
12	OWE-6...Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience. , 2021, , .		0
13	Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E. <i>Blood</i> , 2021, 138, 2411-2411.	0.6	0
14	Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. <i>Frontiers in Oncology</i> , 2021, 11, 785635.	1.3	9
15	The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. <i>Journal of Viral Hepatitis</i> , 2020, 27, 36-44.	1.0	11
16	Prioritising Hepatitis C treatment in people with multiple injecting partners maximises prevention: A real-world network study. <i>Journal of Infection</i> , 2020, 80, 225-231.	1.7	8
17	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.1	1
18	Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use. <i>International Journal of Immunogenetics</i> , 2020, 47, 1-12.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.	2.2	5
20	Natural killer cells target XPO1: a therapeutic opportunity for HCC. <i>Journal of Hepatology</i> , 2020, 73, S647-S648.	1.8	0
21	Identifying the immune interactions underlying HLA class I disease associations. <i>ELife</i> , 2020, 9, .	2.8	17
22	Immunotherapy for hepatocellular carcinoma: Current and future. <i>World Journal of Gastroenterology</i> , 2019, 25, 2977-2989.	1.4	148
23	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. <i>BMJ Open</i> , 2019, 9, e030183.	0.8	9
24	Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 697-709.	1.0	17
25	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	1.9	20
26	PS-027-The LLT1-CD161 interaction: An important inhibitory interaction for NK cells in cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e20-e21.	1.8	0
27	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
28	Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes. <i>Frontiers in Immunology</i> , 2019, 10, 605.	2.2	10
29	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.	0.6	32
30	Generation of functional hepatocyte 3D discoids in an acoustofluidic bioreactor. <i>Biomicrofluidics</i> , 2019, 13, 014112.	1.2	5
31	Constitutive Activation of Natural Killer Cells in Primary Biliary Cholangitis. <i>Frontiers in Immunology</i> , 2019, 10, 2633.	2.2	13
32	Conserved and variable natural killer cell receptors: diverse approaches to viral infections. <i>Immunology</i> , 2019, 156, 319-328.	2.0	28
33	Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma. <i>Hepatology International</i> , 2019, 13, 75-83.	1.9	36
34	A novel antibody combination to identify KIR2DS2 <sup>high</sup> natural killer cells in KIR2DL3/L2/S2 heterozygous donors. <i>Hla</i> , 2019, 93, 32-35.	0.4	7
35	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. <i>Hla</i> , 2018, 92, 3-11.	0.4	10
36	IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells. <i>Immunity, Inflammation and Disease</i> , 2018, 6, 34-46.	1.3	66

#	ARTICLE	IF	CITATIONS
37	Inhibitory killer cell immunoglobulin-like receptors strengthen CD8 <sup>+</sup> T cell-mediated control of HIV-1, HCV, and HTLV-1. <i>Science Immunology</i> , 2018, 3, .	5.6	43
38	Vasoactive intestinal peptide induces proliferation of human hepatocytes. <i>Cell Proliferation</i> , 2018, 51, e12482.	2.4	4
39	Human CD49a+ Lung Natural Killer Cell Cytotoxicity in Response to Influenza A Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1671.	2.2	54
40	STAT4-associated natural killer cell tolerance following liver transplantation. <i>Gut</i> , 2017, 66, 352-361.	6.1	25
41	HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. <i>Journal of Hepatology</i> , 2017, 67, 462-470.	1.8	23
42	KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C. <i>Science Immunology</i> , 2017, 2, .	5.6	78
43	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017, 7, 15843.	1.6	6
44	Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B. <i>Journal of Infection</i> , 2017, 74, 100-102.	1.7	0
45	Hepatitis C bio-behavioural surveys in people who inject drugs—a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling. <i>Harm Reduction Journal</i> , 2017, 14, 44.	1.3	8
46	Hepatitis B virus basal core promoter mutations show lower replication fitness associated with cccDNA acetylation status. <i>Virus Research</i> , 2016, 220, 150-160.	1.1	17
47	Bone marrow transplantation for MHC class I deficiency corrects T-cell immunity but dissociates natural killer cell repertoire formation from function. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1733-1736.e2.	1.5	7
48	Hepatitis B viral replication influences the expression of natural killer cell ligands. <i>Annals of Gastroenterology</i> , 2016, 29, 348-57.	0.4	11
49	The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. <i>Tissue Antigens</i> , 2015, 86, 267-275.	1.0	10
50	NK cells: tuned by peptide?. <i>Immunological Reviews</i> , 2015, 267, 214-227.	2.8	45
51	Innate and adaptive genetic pathways in HCV infection. <i>Tissue Antigens</i> , 2015, 85, 231-240.	1.0	13
52	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , 2015, 9, 251-257.	1.9	14
53	Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals. <i>European Journal of Immunology</i> , 2015, 45, 492-500.	1.6	26
54	Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. <i>Annals of Gastroenterology</i> , 2015, 28, 173-181.	0.4	17

#	ARTICLE	IF	CITATIONS
55	Effects of Peptide on NK Cell-Mediated MHC I Recognition. <i>Frontiers in Immunology</i> , 2014, 5, 133.	2.2	55
56	The Association of Physicians launches new summer research studentships for medical undergraduates. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 787-787.	0.2	0
57	The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads. <i>Clinical Microbiology and Infection</i> , 2014, 20, O325-O332.	2.8	5
58	T cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases. <i>BMC Cancer</i> , 2014, 14, 180.	1.1	23
59	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	2.2	55
60	A Peptide Antagonist Disrupts NK Cell Inhibitory Synapse Formation. <i>Journal of Immunology</i> , 2013, 190, 2924-2930.	0.4	25
61	Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16981-16986.	3.3	26
62	Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. <i>Hepatology</i> , 2013, 58, 881-889.	3.6	19
63	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235.	2.0	187
64	Genetic Variation in the Interleukin-28B Gene Is Associated with Spontaneous Clearance and Progression of Hepatitis C Virus in Moroccan Patients. <i>PLoS ONE</i> , 2013, 8, e54793.	1.1	33
65	NK receptors: it's all in the name. <i>Gut</i> , 2012, 61, 325-326.	6.1	0
66	The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. <i>Human Immunology</i> , 2012, 73, 248-257.	1.2	124
67	Innate immunity: a new chapter for hepatitis C. <i>Annals of Gastroenterology</i> , 2012, 25, 232-240.	0.4	0
68	A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection. <i>Gastroenterology</i> , 2011, 141, 320-325.e2.	0.6	72
69	Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. <i>Current Opinion in Virology</i> , 2011, 1, 497-512.	2.6	124
70	HIV-1 adaptation to NK-cell-mediated immune pressure. <i>Nature</i> , 2011, 476, 96-100.	13.7	310
71	Natural killer cells and hepatitis C: action and reaction. <i>Gut</i> , 2011, 60, 268-278.	6.1	84
72	Understanding the Host Genetics of Chronic Hepatitis B and C. <i>Seminars in Liver Disease</i> , 2011, 31, 115-127.	1.8	85

#	ARTICLE	IF	CITATIONS
73	KIR/HLA Interactions and Pathogen Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	82
74	KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002270.	2.1	67
75	Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen- following exposure to hepatitis C virus. <i>Hepatology</i> , 2010, 51, 1168-1175.	3.6	145
76	Association of NKG2A with treatment for chronic hepatitis C virus infection. <i>Clinical and Experimental Immunology</i> , 2010, 161, 306-314.	1.1	35
77	Peptide antagonism as a mechanism for NK cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10160-10165.	3.3	139
78	The Role of KIR in Disease. , 2010, , 275-298.		1
79	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1536-1545.	0.6	162
80	Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. <i>Journal of Hepatology</i> , 2010, 53, 805-816.	1.8	99
81	Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. <i>Nature</i> , 2009, 461, 798-801.	13.7	2,001
82	Natural killer cells: integrating diversity with function. <i>Immunology</i> , 2009, 126, 449-457.	2.0	107
83	Unexpectedly high incidence of indigenous acute hepatitis E within South Hampshire: Time for routine testing?. <i>Journal of Medical Virology</i> , 2008, 80, 283-288.	2.5	34
84	Speed and selection in the evolution of killer-cell immunoglobulin-like receptors. <i>International Journal of Immunogenetics</i> , 2008, 35, 89-96.	0.8	17
85	Age-Related Macular Degeneration Is Associated with the HLA-Cw*0701 Genotype and the Natural Killer Cell Receptor AA Haplotype. , 2008, 49, 5077.		20
86	KIR and disease: a model system or system of models?. <i>Immunological Reviews</i> , 2006, 214, 186-201.	2.8	248
87	The Inhibitory Receptor NKG2A Determines Lysis of Vaccinia Virus-Infected Autologous Targets by NK Cells. <i>Journal of Immunology</i> , 2006, 176, 1141-1147.	0.4	30
88	HANGING IN THE BALANCE: KIR and Their Role in Disease. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 226-240.	3.4	96
89	HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection. <i>Science</i> , 2004, 305, 872-874.	6.0	1,086
90	Expression of MHC Class I Receptors Determines Natural Killer Cell Lysis of Vaccinia Virus Infected Cells. <i>Clinical Science</i> , 2003, 104, 51P-51P.	0.0	0

#	ARTICLE	IF	CITATIONS
91	MHC class I receptors on natural killer cells: on with the old and in with the new. <i>Clinical Science</i> , 2003, 105, 127-140.	1.8	4
92	The D0 Domain of KIR3D Acts as a Major Histocompatibility Complex Class I Binding Enhancer. <i>Journal of Experimental Medicine</i> , 2002, 196, 911-921.	4.2	67
93	Conservation and Variation in Human and Common Chimpanzee <i>CD94</i> and <i>NKG2</i> Genes. <i>Journal of Immunology</i> , 2002, 168, 240-252.	0.4	86
94	Comparison of Chimpanzee and Human Leukocyte Ig-Like Receptor Genes Reveals Framework and Rapidly Evolving Genes. <i>Journal of Immunology</i> , 2001, 167, 5786-5794.	0.4	53
95	Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. <i>Gut</i> , 2000, 47, 137-143.	6.1	22
96	Rapid Evolution of NK Cell Receptor Systems Demonstrated by Comparison of Chimpanzees and Humans. <i>Immunity</i> , 2000, 12, 687-698.	6.6	271
97	Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection. <i>Hepatology Research</i> , 1998, 11, 158-165.	1.8	6
98	Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 563-570.	1.1	133
99	Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. <i>American Journal of Pathology</i> , 1997, 150, 963-70.	1.9	54
100	HCV-associated hepatocellular carcinoma without cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 277-285.	1.8	78
101	A clinical evaluation of a new method for HBV DNA quantitation in patients with chronic hepatitis B. , 1996, 50, 112-116.		10
102	Hepatotoxicity and Accelerated Fibrosis Following 3,4-Methylenedioxymetamphetamine (‘Ecstasy’) Usage. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 244-247.	1.1	54
103	Histological assessment of the Sydney classification of endoscopic gastritis.. <i>Gut</i> , 1994, 35, 1172-1175.	6.1	89
104	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. <i>Wellcome Open Research</i> , 0, 7, 51.	0.9	0
105	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. <i>International Journal of Epidemiology</i> , 0, , .	0.9	2